CHEMICAL & ENGINEERING NEWS (ACS PUBLICATIONS)
C&EN's 2019 10 Start-Ups to Watch

"Gene therapy manufacturing 'is 20 years behind' academic research in gene delivery and is a concern to investors.”

- Louis Maranga, Chief Technical Operations Officer, Voyager Therapeutics

"You can have the fanciest ideas and molecules, but if you can't get them into the cell, they are of no use.”

- Matthew Porteus, co-founder, crispr therapeutics

Gene therapy has a delivery problem.
​ligandal has a solution.

THE PROBLEM

Genes don't pass the cell membrane on their own, and gene therapies are limited in which cells can be targeted.

THE SOLUTION

Ligandal makes custom binding peptides that shuttle genes into specifically targeted cells.

The vision

We want to see gene therapy widely available to the masses, for reprogramming virtually any disease state.

DISCOVER OUR PROCESS & SCIENCE

Ligandal aims to democratize personalized medicine, providing customized gene therapies at 100x cost reduction.